Keystone Symposia | Scientific Conferences on Biomedical and Life Science Topics

Advances in the Understanding and Treatment of Melanoma (A6)

Organizer(s): Patrick Hwu, Elizabeth Grimm and James Mulé
January 18 - 23, 2006
Hilton Santa Fe/Historic Plaza · Santa Fe, New Mexico
Abstract Deadline: September 19, 2005
Late Abstract Deadline: October 11, 2005
Scholarship Deadline: September 19, 2005
Early Registration Deadline: November 18, 2005

Supported by The Director's Fund

The University of Colorado School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The University of Colorado School of Medicine designates this educational activity for a maximum of 28-35 category 1 credits toward the AMA Physician's Recognition Award. Each physician should claim only those credits that he/she actually spent in the activity.

To receive CME credits, mark the box on the registration form, and pay the additional $50.00.

This meeting took place in the 2006 season.

For a complete list of the meetings for the upcoming/current season,
see our meeting list, or search for a meeting.

Summary of Meeting
Because of its inherent immunogenicity and abundant vascularity, melanoma provides a unique opportunity to develop novel molecular, immunologic and anti-angiogenic therapies that can then be generalized to other diseases. Some consider melanoma the "E.coli" in which to develop new cancer therapies. Three of the most exciting areas in this field involve molecular targeting of specific pathways, cancer vaccines and immunotherapy, and anti-vascular therapies. However, none of these areas alone are likely to have significant impact in the disease, and the use of multiple approaches will be critical. While there are many meetings which focus on a particular treatment approach, this program will bring together a multidisciplinary group that will explore the interactions among these distinct therapeutic strategies. We envision that basic and clinical research in melanoma will lead the way in integrating molecular targeting, immunologic, and anti-vascular therapies and can serve as a model for the treatment of other diseases.

Objectives
Upon completion of this conference, participants should be able to:

To summarize the current understanding of the major signaling pathways that lead to melanoma.
To describe strategies to translate new molecular findings to the clinic.
To define rationale strategies to combine diverse approaches to melanoma.
To explain the major scientific and logistical challenges that inhibit the ability to rapidly move new concepts into the clinic.

Wednesday, January 18
3:00 - 7:30 PM	Registration	Promenade
6:30 - 7:30 PM	Refreshments	Promenade
7:30 - 8:30 PM	Keynote Address	Mesa A-B
	Richard M. Marais, Institute of Cancer Research Mechanisms of RAF Signaling in Cancer
Thursday, January 19
7:00 - 8:00 AM	Breakfast	Chamisa
8:00 - 11:00 AM	Epidemiology and Prevention of Melanoma	Mesa A-B
	Margaret A. Tucker, National Cancer Institute, National Institutes of Health Who is at Risk of Melanoma?

	* Marianne Berwick, University of New Mexico Health Sciences Center Gene-Environment Interactions in Melanoma
	Qingyi Wei, University of Texas MD Anderson Cancer Center DNA Repair and Susceptibility to Melanoma
	Christina K. Augustine, Duke University and VA Medical Centers Short talk: Optimizing Regional Melanoma Therapy Using Pharmacogenomic Strategies
9:20 - 9:40 AM	Coffee Break	Promenade
11:00 AM - 1:00 PM	Poster Setup	Ortiz
1:00 - 10:00 PM	Poster Viewing	Ortiz
2:00 - 4:30 PM	Workshop 1: Melanoma Immunotherapy	Mesa A-B
	* Bernard A. Fox, Earle A. Chiles Research Institute Exploiting Lymphopenia to Augment Vaccine Efficacy
	* James J. Mulé, H. Lee Moffitt Cancer Center & Research Institute
	Daniel E. Speiser, Ludwig Institute for Cancer Research Ex Vivo Detectable Human CD8 T-Cell Responses to CT Antigens in 4/4 Patients Vaccinated with Stable Peptide / IFA Emulsions
	Jedd D. Wolchok, Memorial Sloan-Kettering Cancer Center Clinical Development of DNA Vaccines for Melanoma
	Christopher A. Klebanoff, National Cancer Institute, National Institutes of Health Removal of Homeostatic Cytokine Sinks by Lymphodepletion Enhances the Efficacy of Adoptively Transferred Tumor-Specific CD8+ T Cells
	Karen Hastings, University of Arizona College of Medicine, Phoenix Lysosomal Thiol Reductase GILT is Essential for MHC Class II Processing of Melanocyte Differentiation Antigen TRP-1
4:30 - 5:00 PM	Coffee Available	Promenade
5:00 - 7:00 PM	Prognostic Markers for Melanoma Progression	Mesa A-B
	* James J. Mulé, H. Lee Moffitt Cancer Center & Research Institute
	David S.B. Hoon, John Wayne Cancer Institute Prognostic Markers for Melanoma Progression
	David E. Elder, University of Pennsylvania School of Medicine Markers of Tumor Progression, Diagnosis and Prognosis in Melanoma
	David Rimm, Yale University Quantitative Multiplexed Analysis of TMAs to Discover Prognostic Factors for Melanoma
7:00 - 8:00 PM	Social Hour w/ Lite Bites	Ortiz/Chamisa
7:30 - 10:00 PM	Poster Session 1	Ortiz/Chamisa
Friday, January 20
7:00 - 8:00 AM	Breakfast	Chamisa
8:00 - 11:00 AM	Molecular Biology of Melanoma I	Mesa A-B
	* Meenhard Herlyn, Wistar Institute Targeting Signaling Pathways for Melanoma Therapy
	Peter Hersey, University of Newcastle TRAIL Biology and Melanoma

	Ann Richmond, Vanderbilt University School of Medicine Targeting NF-kappaB and Autocrine Signaling Pathways in Melanoma
	Bahija Jallal, MedImmune, Inc. Targeted Therapeutics in Melanoma: Changing the Front End of Drug Development
	Penny Emma Lovat, University of Newcastle Upon Tyne Short Talk: Fenretinide-Induced Apoptosis Via Endoplasmic Reticulum Stress- New Drug Targets for Melanoma Therapy?
9:20 - 9:40 AM	Coffee Break	Promenade
2:00 - 4:30 PM	Workshop 2: Staging and Biomarkers	Mesa A-B
	* Vernon K. Sondak, H. Lee Moffitt Cancer Center & Research Institute The Need for New Biomarkers of Melanoma Nodal Metastasis
	* Merrick I. Ross, University of Texas MD Anderson Cancer Center Future Approaches to Melanoma Staging

	Steven Everett, Ninewells Hospital & Medical School Cytochrome P450 Cyp1b1 Expression in Primary and Metastatic Melanoma
	Stergios Moschos, University of Pittsburgh Medical Center Ubc9, is the Most Highly Expressed Protein in Melanoma Infiltrated Lymph Nodes and its Downregulation, Alone or in Combination with Chemotherapy/Radiation, Increases Cell Death in Melanoma Cell Lines
	Phyllis A. Gimotty, University of Pennsylvania Staging Thin (< 1.00mm) Invasive Cutaneous Melanomas
	Rosalynn M. Nazarian, Massachusetts General Hospital Mitf, Bcl-2 and Inos Expression in Melanocytic Tumor Progression Using a Tissue Microarray Approach
	Jeffrey E. Gershenwald, University of Texas MD Anderson Cancer Center Heterogeneity of Microscopic Stage III Melanoma in the SLN Era: Implications for AJCC/UICC Staging and Future Clinical Trial Design
4:30 - 5:00 PM	Coffee Available	Promenade
5:00 - 7:00 PM	Molecular Biology of Melanoma II	Mesa A-B
	Frank Meyskens, University of California, Irvine The Pathogenesis of Human Melonoma is a Redox-Driven/Regulated Process: Etiologic, Preventitive and Therapeutic Implications
	* Elizabeth A. Grimm, University of Texas MD Anderson Cancer Center Role of Endogenous Nitric Oxide in Melanoma
	Somasekar Seshagiri, Genentech, Inc. Short Talk: Oncogenic BRAF is Required for Tumor Growth and Maintenance in Melanoma Models
7:00 - 8:00 PM	Social Hour w/ Lite Bites	Ortiz/Chamisa
Saturday, January 21
7:00 - 8:00 AM	Breakfast	Chamisa
8:00 - 11:00 AM	Preclinical Studies of Melanoma Immunotherapy	Mesa A-B

	Herbert B. Slade, DFB Pharmaceuticals Application of Toll-Like Receptor 7/8 Agonists in Cancer Therapy
	Suzanne L. Topalian, Johns Hopkins University School of Medicine Melanoma-Associated Genetic Mutations Targeted by Human CD4+ T Cells
	* Patrick Hwu, University of Texas MD Anderson Cancer Center Murine Plasmacytoid Dendritic Cells Synergize with Myeloid Dendritic Cells and NK Cells in the Induction of Anti-Tumor Immune Responses In Vivo
	Giorgio Parmiani, San Raffaele Foundation Scientific Institute New Immunosuppressive Mechanisms in Melanoma Patients
	Thomas S. Kupper, Brigham and Women's Hospital, Harvard Medical School Short Talk: Approaches to Optimizing Melanoma Immunotherapy
9:20 - 9:40 AM	Coffee Break	Promenade
11:00 AM - 1:00 PM	Poster Setup	Ortiz
1:00 - 10:00 PM	Poster Viewing	Ortiz
2:00 - 4:30 PM	Panel Discussion: Overcoming Barriers to Translational Research	Mesa A-B
	* Lynn Schuchter, University of Pennsylvania
	* Walter J. Urba, Earle A. Chiles Research Institute
	Francesco M. Marincola, National Cancer Institute, National Institutes of Health Title to be Determined
4:30 - 5:00 PM	Coffee Available	Promenade
5:00 - 7:00 PM	Melanoma Clinical Immunotherapy Trials	Mesa A-B


	* Jeffrey Weber, H. Lee Moffitt Cancer Center Phase II Trials of Class II Melanoma Peptides and Class I Peptides with IL-12 and Alum for Resected High Risk Melanoma
	Thomas F. Gajewski, University of Chicago Gene Expression Profile of Melanoma Tumor Microenvironment Associated with Favorable Clinical Outcome to a Multipeptide Vaccine
	Anna Karolina Palucka, Baylor Institute for Immunology Research Dendritic Cell Vaccines in Melanoma
	F. Stephen Hodi, Dana Farber Cancer Institute Short Talk: Cytotoxic T Lymphocyte-Associated Antigen-4 (CTLA-4) Antibody Blockade in Previously Vaccinated Melanoma and Ovarian Cancer Patients
7:00 - 8:00 PM	Social Hour w/ Lite Bites	Ortiz/Chamisa
7:30 - 10:00 PM	Poster Session 2	Ortiz/Chamisa
Sunday, January 22
7:00 - 8:00 AM	Breakfast	Chamisa
8:00 - 11:00 AM	Antivascular Approaches for Melanoma	Mesa A-B
	* Menashe Bar-Eli, University of Texas MD Anderson Cancer Center Gene Regulation in Melanoma Angiogenesis
	Mary J.C. Hendrix, Children's Memorial Research Center at Northwestern University The Clinical Implications of Melanoma Tumor Cell Plasticity
	Wen-Jen Hwu, University of Texas MD Anderson Cancer Center Treatment of Melanoma with Thalidomide and Its Analogues: Antivascular, and Immunomodulatory Activity
	Steven K. Libutti, Albert Einstein College of Medicine Clinical Trials of Antivascular Agents in Melanoma
9:20 - 9:40 AM	Coffee Break	Promenade
2:00 - 4:30 PM	Workshop 3: Melanoma Signal Transduction and Targeted Therapies	Mesa A-B
	* Frank G. Haluska, Massachusetts General Hospital
	* Jeffrey E. Lee, University of Texas MD Anderson Cancer Center
	Staffan Stromblad, Karolinska Institutet Rescue of Integrin alphaV-Dependent Unfolding of Wild Type p53 Suppresses Melanoma Tumor Growth
	Romina Marone, Institute of Biochemistry and Genetics Targeting Melanoma – Which Phosphoinositide 3-Kinase Isoform?
	Kevin B. Kim, University of Texas MD Anderson Cancer Center Changes in Expressions of Phosphorylated-AKT in Metastatic Melanoma Lesions after Imatinib Treatment

	Alexander J.F. Lazar, University of Texas MD Anderson Cancer Center PTEN Expression, BRAF and NRAS Mutational Status in Primary Cutaneous Melanoma
4:30 - 5:00 PM	Coffee Available	Promenade
5:00 - 5:45 PM	Workshop 4: Epidemiology and Molecular Biology	Mesa A-B
	* Thomas S. Kupper, Brigham and Women's Hospital, Harvard Medical School
	Craig Ceol, Children's Hospital Boston Short Talk: Using the Zebrafish to Identify and Characterize Mutations that Cause Melanoma
	Michael Ming, University of Pennsylvania Short Talk: Statins, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and Calcium Channel bBockers (CCBs) are Prescribed Less Frequently for Patients who Later Develop Melanoma
	Levi A. Garraway, Dana Farber Cancer Institute Short Talk: Linking Genetic Dependency to Therapeutic Vulnerability in Melanoma
5:45 - 6:45 PM	Concluding Keynote Address	Mesa A-B
	Michael B. Atkins, Harvard Medical School The Future of Melanoma Therapy
6:45 - 7:00 PM	Announcement of Poster Contest Winners
	* Patrick Hwu, University of Texas MD Anderson Cancer Center
7:00 - 8:00 PM	Social Hour w/ Lite Bites	Mesa C
8:00 - 11:00 PM	Entertainment	Mesa C
Monday, January 23
	Departure

*Session Chair †Speaker invited, not yet responded.